Filing Flows › Gossamer Bio (GOSS) › Q4 2024
Gossamer Bio (GOSS) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 13, 2025
Gossamer Bio (GOSS) reported revenue of $9.4M for the fourth quarter 2024 (Q4 2024) and -1% from the quarter before. Operating margin was -385.2%, net loss $33.0M (352.2% of revenue).
Gossamer Bio, Q4 2024: revenue $9.4M, operating margin -385.2%, net loss $33.0M, operating cash flow −$35.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $9.4M | -1% | — |
| Operating profit | −$36.1M | — | — |
| Net earnings | −$33.0M | — | — |
| Operating cash flow | −$35.5M | — | — |
What changed
Revenue was $9.4M in Q4 2024, down 1% from the previous quarter. Revenue from contracts with collaborators was the largest line at 79% of revenue.
Operating costs exceeded revenue by $36.1M, an operating margin of -385.2%. The quarter ended with a net loss of $33.0M, wider than the previous quarter's $30.8M loss.
Operating cash flow was −$35.5M. Non-cash charges added back $108K of depreciation and amortization and $5.0M of share-based compensation. Working capital and other items used $7.5M.
Questions
What was Gossamer Bio's revenue in the fourth quarter 2024?
Gossamer Bio (GOSS) reported revenue of $9.4M for the fourth quarter 2024 (Q4 2024) and -1% from the quarter before.
Was Gossamer Bio profitable in the fourth quarter 2024?
Operating loss was $36.1M (-385.2% of revenue) and net loss $33.0M.
Source: Gossamer Bio 10-K on SEC EDGAR.